

ASX:VIT

ASX ANNOUNCEMENT RELEASE OF SHARES FROM VOLUNTARY ESCROW

18 APRIL 2024

Melbourne, Australia – Vitura Health Limited (ASX: VIT) **(Vitura** and **Company)** announces that, in accordance with Listing Rule 3.10A, a total of 8,690,211 fully paid ordinary shares in the Company (**Shares**), which are currently subject to voluntary escrow, will be released from escrow at 12.00 am (Melbourne time) on Monday, 29 April 2024.

Details of the six-month voluntary escrow arrangements were released to the ASX on 19 October 2023 in relation to its acquisition of Doctors on Demand Pty. Ltd. that was completed on 26 October 2023.

The Company confirms that, following the release of the Shares from escrow, there will be no further shares in the Company that are subject to escrow.

** FNDS **

VITURA HEALTH LIMITED

ASX : VIT

PO Box 6168, South Yarra Victoria 3141, Australia VITURA.COM.AU













About Vitura Health Limited (ASX:VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

• www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy and supplier online ecosystem, Canview, which sells and distributes 440+ therapeutic product and device SKUs within Australia from approximately 42 international and domestic brands.

• www.canview.com.au

CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,400 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

• <u>www.doctorsondemand.com.au</u>

The Company owns Doctors on Demand Pty Ltd, a nationwide $24/7 \times 365$ telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, medicated weight loss and smoking cessation.

• www.cortexa.com.au

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.



• www.cdaclinics.com.au

The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

• www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

Authorised by

Rodney Cocks, Chief Executive Officer

Contact

Vitura Health Limited

Rodney Cocks Chief Executive Officer 1300 799 491 info@vitura.com.au

Media enquiries

Tim Fogarty
The Civic Partnership
+61 400 179 075
tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.